CEO of Japanese ophthalmology specialist lays out clear-sighted business vision as track laid for expansion into global markets and new indications amid expiry challenges at home. New modalities are also being explored to meet needs in demanding disorders, Shigeo Taniuchi tells Scrip in an exclusive interview. 

Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.

The Phase II trial showed significant improvement in eye redness in patients with dry eye disease, but additional data are needed on DED symptom improvement.

AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.